Importance of creatinine analyses of urine when screening for abused drugs

1991 ◽  
Vol 37 (11) ◽  
pp. 1927-1931 ◽  
Author(s):  
P Lafolie ◽  
O Beck ◽  
G Blennow ◽  
L Boréus ◽  
S Borg ◽  
...  

Abstract We report here a simple method involving urine creatine measurements for testing authenticity and reducing false-negative results in urine testing for drugs of abuse. Urinary creatinine in consecutive patient samples (n = 176) ranged between 0.1 and 31.9 mmol/L (mean 9.8 +/- SD 6.2) and the osmolality in these urines ranged between 49 and 1183 mOsm/kg (mean 595 +/- SD 276). With other consecutive samples in which creatinine was (arbitrarily chosen) less than 4.3 mmol/L (n = 85), the correlation with osmolality was lower. In 10 randomly selected urine samples from different patients, all "clean" for all drugs of abuse in initial immunological drug testing with approved methodology (in which creatinine was less than 4.3 mmol/L and osmolality was less than 200 mOsm/kg), five patients turned out to be drug positive after a simple concentration by volume. In a formerly heavy smoker of cannabis, the excretion of cannabinoids and creatinine was monitored for 93 days. The substances showed very good correlation throughout this period (r = 0.93, P less than 0.001), whereas simple measurements of cannabinoid concentrations would have falsely indicated several relapses of cannabis abuse. Urine samples used in drug-abuse testing should be tested for creatinine; if creatinine is less than 4.0 mmol/L, negative results for drugs may not be valid.

Author(s):  
Barbara Matriciani ◽  
Bernd Huppertz ◽  
Ruprecht Keller ◽  
Ralf Weiskirchen

Background The dilution or adulteration of urine is a serious problem in drugs of abuse testing. Tests to identify adulteration are currently available. This study investigated the ability of the CEDIA® sample check to detect adulteration. Methods Eight different drugs of abuse were added to a urine sample obtained from a healthy, drug-free subject: 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP), 3,4-methylenedioxyamphetamine, benzoylecgonine, D-amphetamine sulphate, ethyl-D-glucuronide, morphine sulphate, oxazepam, (-)-11-nor-9-carboxy-Δ9-tetrahydrocannabinol. Urine samples were diluted to yield three samples of drugs of abuse concentrations close to general cut-offs as used in methadone treatment centres, by health authorities for psychological tests and in traffic medicine. Aspirin, citric acid, CrO3, H2O2, soap, sodium metaborate, vitamin C were added in three, HCl and NaOH in one, and NaN3 in two concentrations. All samples were measured with commercially available immunological assays shortly after sample preparation and 24 h later. All samples were further analysed with the CEDIA® sample check reaction which may identify adulteration. Results Oxidizing reagents (H2O2 or CrO3) are most effective in interfering in the measurement of benzoylecgonine, EDDP, ethyl-D-glucuronide and morphine sulphate. The measurement of (-)-11-nor-9-carboxy-Δ9-tetrahydrocannabinol is affected by many adulterants. Adulteration with HCl and NaOH was identified with the sample check reaction. NaN3 generated false negative results for a number of drugs of abuse. Conclusions Urine samples with drugs of abuse concentrations above cut-offs can be successfully tampered with adulterants in a way which cannot be detected with the CEDIA® sample check assay.


Author(s):  
Tarek Mahdy ◽  
Abdulaziz Al-Sulaiti ◽  
Yasser Abdelqader ◽  
Abdelrahman Fikry ◽  
Gaffar Hag ◽  
...  

Many false positive and false negative results have been detected in immunoassay analyses of drugs of abuse in urine samples. A method of direct injection of diluted urine into LC/MS/MS was developed and validated for detection and quantitation of Amphetamine, Methamphetamine, MDMA, MDA, Benzoylecgonine, Ecgonine, Norpseudoephedrine, Ephedrine, Tapentadol, Tramadol, O-desmethyltramadol, Tapentadol, Pregabline, Gabapentine and Methadone to avoid the false positive and false negative results in urine samples. Linearity of Amphetamine, Methamphetamine MDMA, MDA, Benzoylecgonine, Ecgonine, Norpseudoephedrine and Ephedrine was (60-2400ng/mL), for Tapentadol, Tramadol, O-desmethyltramadol, and Methadone was (50-1600 ng/mL), and for Pregabline and Gabapentine was (100-4000ng/mL) and r2 ˃ 0.992 for all analysts. A 440 urine samples have been analyzed using both immunoassay technique and LC/MS/MS by direct injection method giving a good comparison to illustrate how this method was specific, accurate, precise, and applicable for forensic urine samples


2010 ◽  
Vol 134 (5) ◽  
pp. 735-739 ◽  
Author(s):  
Stacy E. F. Melanson ◽  
Leland Baskin ◽  
Barbarajean Magnani ◽  
Tai C. Kwong ◽  
Annabel Dizon ◽  
...  

Abstract Context.—To assist with patient diagnosis and management, physicians from pain services, drug treatment programs, and the emergency department frequently request that urine be tested for drugs of abuse. However, urine immunoassays for drugs of abuse have limitations. Objective.—To use data from the College of American Pathologists Proficiency Testing Surveys to determine and summarize the characteristics, performance, and limitations of urine immunoassays for drugs of abuse. Design.—Six years of urine drug testing proficiency surveys were reviewed. Results.—Lysergic acid diethylamide and methaqualone are infrequently prescribed or abused and, therefore, testing may be unnecessary. However, implementation of more specific testing for methylenedioxymethamphetamine and oxycodone may be warranted. Each drug of abuse immunoassay exhibits a different cross-reactivity profile. Depending on the cross-reactivity profile, patients with clinically insignificant concentrations of drugs may have false-positive results, and patients with clinically significant concentrations of drugs may have false-negative results. Conclusions.—Laboratory directors should be aware of the characteristics of their laboratories' assays and should communicate these characteristics to physicians so that qualitative results can be interpreted more accurately. Furthermore, manufacturer's claims should be interpreted with caution and should be verified in each organization's patient population, if possible.


1992 ◽  
Vol 38 (6) ◽  
pp. 803-807 ◽  
Author(s):  
J G de Jong ◽  
R A Wevers ◽  
R Liebrand-van Sambeek

Abstract Earlier we described a simple and reliable screening procedure in urine for mucopolysaccharidoses based on the color reaction of glycosaminoglycans (GAGs) with dimethylmethylene blue. At physiological concentrations of urinary protein, we observed an obvious interference by protein in the assay. By modifying the assay, we abolished the protein interference. The modified procedure is not disturbed by human serum albumin, IgG (both tested with as much as 5 g/L of protein), or urinary proteins. The modified procedure appeared as reliable as the original. No false-negative results were found in a series of 26 urine samples from patients with mucopolysaccharidoses (sensitivity 100%). In a series of 405 urine samples offered for metabolic screening, 24 samples with increased GAG content and normal GAG composition were seen (specificity 94%). The method may also be applicable for determining GAG in other body fluids or solutions containing protein.


2008 ◽  
Vol 13 (5) ◽  
pp. 319-324 ◽  
Author(s):  
M. Hedayati ◽  
A. Tajic ◽  
M. S. Daneshpour ◽  
A. Kazemi

1981 ◽  
Vol 9 (4) ◽  
pp. 381-386 ◽  
Author(s):  
David Sage

Intradermal testing of intravenous anaesthetic drugs was performed on 34 patients following acute anaphylactoid reactions during anaesthesia. Twenty-three patients had positive skin tests and 18 of these were positive for a single drug. Muscle relaxants were the drugs implicated most commonly. Intradermal testing is safe and provides useful and often specific positive information, but false-negative results probably occur.


1991 ◽  
Vol 37 (4) ◽  
pp. 572-575 ◽  
Author(s):  
J G N de Jong ◽  
J J F Hasselman ◽  
A A J van Landeghem ◽  
H L Vader ◽  
R A Wevers

Abstract To check the reliability of the Ames MPS paper spot test, which is based on the Azure A dye, we sent a series of urine samples to three laboratories where the spot test is part of the metabolic screening for mucopolysaccharidoses. In these laboratories false-negative results ranged between 19% and 35% and false-positive results ranged between 12% and 29% of all samples submitted. In contrast, the quantitative dimethylmethylene blue test (Clin Chem 1989;35:1472-7) detected an increased glycosaminoglycan content in all urine samples from mucopolysaccharidosis patients and gave no false-positive results. In the latter procedure, glycosaminoglycan content is expressed per millimole of creatinine, and age-dependent reference values are used. We conclude that the Ames spot test and other spot tests are unreliable as a screening procedure for mucopolysaccharidoses and should not be used to screen for these diseases.


1994 ◽  
Vol 40 (4) ◽  
pp. 608-612 ◽  
Author(s):  
R E Wagener ◽  
M W Linder ◽  
R Valdes

Abstract During routine drug analysis with the Syva d.a.u. Emit immunoassays we observed a high frequency of urines with lower rates of changes in absorbance (delta A R) than the rate for a drug-free urine calibrator. Many of these urines contained salicylates. Among 40 urines with apparent salicylate concentrations between 15 and 420 mg/dL tested for benzoylecgonine (BE), 20 had delta A R < -4 (range +2 to -28 mA/min). The rates decreased with increasing salicylate: delta A R = -0.057 x (salicylate, mg/dL) -0.22 mA/min (r = 0.85, n = 40, P < 0.01). Urines from 100 control subjects (no salicylate) had mean +/- SD delta A R values of -1.05 +/- 2.2 mA/min (range +3 to -7; only two were < -4 mA/min). Although direct addition of salicylic acid (200 mg/dL) to urine specimens did not reproduce the negative bias, ingestion of aspirin (acetylsalicylic acid) did by -0.09 mA/min per 1 mg/dL (72.4 mumol/L) salicylate. Negative biases observed for other Emit d.a.u. assays after salicylate ingestion lead us to conclude that ingestion of therapeutic doses of aspirin may cause false-negative results for drug screens in urines by this technology.


Sign in / Sign up

Export Citation Format

Share Document